Printer Friendly

MAGAININ PHARMACEUTICALS INC. FILES FOR PROPOSED PUBLIC OFFERING

 PLYMOUTH MEETING, Penn., Dec. 15 /PRNewswire/ -- Magainin Pharmaceuticals Inc. (NASDAQ: MAGN) today announced that it has filed a registration statement with the Securities and Exchange Commission for a proposed public offering of 3,500,000 shares of common stock. All of the shares will be sold by the company.
 The offering is being managed by Hambrecht & Quist Incorporated, Smith Barney, Harris Upham & Co. and S.G. Warburg Securities.
 Magainin Pharmaceuticals Inc. is a biopharmaceutical company engaged in the research and development of anti-infectives and anti-cancer products based upon compounds isolated from the host-defense systems of animals.
 A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. The securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration of qualification under the securities laws of any such state or jurisdiction.
 Copies of the preliminary prospectus relating to the offering may be obtained from Hambrecht & Quist Incorporated, Smith Barney, Harris Upham & Co., or S.G. Warburg Securities.
 -0- 12/15/92
 /CONTACT: Jay Moorin of Magainin Pharmaceuticals Inc. 215-941-4020, or Fern Lazar or Debra Wasser of Dewe Rogerson, 212-688-6840, for Magainin Pharmaceuticals/
 (MAGN)


CO: Magainin Pharmaceuticals Inc. ST: Pennsylvania IN: MTC SU: OFR

LD-SM -- NY081 -- 7438 12/15/92 17:29 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 15, 1992
Words:268
Previous Article:MICROPROSE RELEASES F-15 STRIKE EAGLE III FOR CHRISTMAS
Next Article:ENNIS BUSINESS FORMS, INC. REPORTS NINE MONTHS OPERATING RESULTS
Topics:


Related Articles
ISIS PHARMACEUTICALS FILES PUBLIC OFFERING FOR 2 MILLION SHARES OF COMMON STOCK
MAGAININ PHARMACEUTICALS RECEIVES PATENT FOR WOUND HEALING DRUGS
MAGAININ PHARMACEUTICALS ANNOUNCES DISCOVERY OF FIRST STEROID HOST-DEFENSE ANTIBIOTIC
SCIENTISTS ISOLATE NEW ANTIBIOTICS FROM SHARK
SPARTA PHARMACEUTICALS INC. ANNOUNCES PROPOSED INITIAL PUBLIC OFFERING
ARONEX PHARMACEUTICALS, INC. PLANS A PUBLIC OFFERING OF 6,000,000 SHARES OF COMMON STOCK
Magainin Pharmaceuticals Raises $12 Million in Private Placement
Magainin Pharmaceuticals Buys Out MSI-78 Royalty Stream
InKine Pharmaceutical - Formerly Panax Pharmaceutical Completes $17 Million Private Financing
Magainin Pharmaceuticals Inc. Announces Over-Allotment Option Exercised

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters